CLASS ACTION UPDATE for VWE, SPPI and SUNL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / January 10, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

VWE Shareholders Click Here: https://www.zlk.com/pslra-1/vintage-wine-estates-class-action-lawsuit-submission-form?prid=35486&wire=1
SPPI Shareholders Click Here: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-lawsuit-submission-form?prid=35486&wire=1
SUNL Shareholders Click Here: https://www.zlk.com/pslra-1/sunlight-financial-lawsuit-submission-form?prid=35486&wire=1

* ADDITIONAL INFORMATION BELOW *

Vintage Wine Estates, Inc. VWE

VWE Lawsuit on behalf of: investors who purchased October 13, 2021 - September 13, 2022
Lead Plaintiff Deadline : January 13, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/vintage-wine-estates-class-action-lawsuit-submission-form?prid=35486&wire=1

According to the filed complaint, during the class period, Vintage Wine Estates, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) due to a material weakness related to its inventory controls and procedures, the Company lacked a reasonable basis to report inventory metrics; (2) the Company understated its overhead burden in certain quarters, thereby overstating its adjusted EBITDA; (3) as a result of the foregoing, Vintage Wine was reasonably likely to incur significant charges to restate prior reporting; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Spectrum Pharmaceuticals, Inc. SPPI

This lawsuit is on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. common stock during the period December 6, 2021 through September 22, 2022, inclusive.
Lead Plaintiff Deadline : February 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-lawsuit-submission-form?prid=35486&wire=1

According to the filed complaint, defendants were conducting a phase 2 clinical trial called ZENITH20, which was an ongoing, multicenter, multi-cohort, open-label, activity-estimating study evaluating the anti-tumor effects, safety, and tolerability of poziotinib in patients with locally advanced or metastatic non-small cell lung cancer that have certain mutations and were previously treated with the standard of care. Although defendants represented that the safety and efficacy data from the ZENITH20 trial were positive and that they had initiated a required confirmatory phase 3 study, on September 20, 2022, a briefing document from the United States Food and Drug Administration Oncologic Drugs Advisory Committee disclosed not only negative data on the safety and efficacy of poziotinib, but also a failure by the Company to enroll any patients in a required phase 3 confirmatory trial.

Sunlight Financial Holdings Inc. f/k/a Spartan Acquisition Corp. II SUNL

SUNL Lawsuit on behalf of: investors who purchased January 25, 2021 - September 28, 2022
Lead Plaintiff Deadline : February 14, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/sunlight-financial-lawsuit-submission-form?prid=35486&wire=1

According to the filed complaint, during the class period, Sunlight Financial Holdings Inc. f/k/a Spartan Acquisition Corp. II made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked effective underwriting and risk evaluation with respect to its contractor advance program; (2) Sunlight lacked the oversight and periodic monitoring systems necessary to timely detect bad debt associated with its contractor advance program; (3) the Company lacked effective internal controls over accounting and reporting of non-cash advance receivables; (4) as a result, the Company would be forced to take a non-cash advance receivables impairment charge exceeding $30 million; and (5) as a result of the foregoing, defendant's positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP